Latest Stocks: Elkfork Partners LLC Holds Stake in NewLink Genetics Corp (NLNK)

Latest Stocks: Elkfork Partners LLC Holds Stake in NewLink Genetics Corp (NLNK)

Elkfork Partners LLC continued to hold its stake in shares of NewLink Genetics Corp (NASDAQ:NLNK) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 15,290 shares of the biotechnology company’s stock at the end of the first quarter. Elkfork Partners LLC owned 0.05% of NewLink Genetics Corp worth $368,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of NewLink Genetics Corp by 0.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 164,312 shares of the biotechnology company’s stock valued at $2,468,000 after buying an additional 1,181 shares during the period. Knoll Capital Management LP acquired a new position in NewLink Genetics Corp during the third quarter worth $1,504,000. State Street Corp raised its position in NewLink Genetics Corp by 5.7% in the fourth quarter. State Street Corp now owns 430,428 shares of the biotechnology company’s stock worth $4,422,000 after buying an additional 23,029 shares during the last quarter. Northwest Wealth Management LLC acquired a new position in NewLink Genetics Corp during the fourth quarter worth $863,000. Finally, Dimensional Fund Advisors LP raised its position in NewLink Genetics Corp by 49.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 63,978 shares of the biotechnology company’s stock worth $658,000 after buying an additional 21,248 shares during the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

Shares of NewLink Genetics Corp (NASDAQ NLNK) opened at 11.03 on Tuesday. The company’s 50-day moving average is $16.31 and its 200 day moving average is $15.11. NewLink Genetics Corp has a 52 week low of $9.66 and a 52 week high of $25.17. The stock’s market capitalization is $322.35 million.

NewLink Genetics Corp (NASDAQ:NLNK) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.10. The firm had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $2.68 million. NewLink Genetics Corp had a negative return on equity of 68.81% and a negative net margin of 757.44%. On average, equities analysts forecast that NewLink Genetics Corp will post ($2.75) EPS for the current fiscal year. Several research firms have weighed in on NLNK. Cantor Fitzgerald reiterated an “overweight” rating and issued a $32.00 target price (up from $20.00) on shares of NewLink Genetics Corp in a report on Saturday, April 22nd. Jefferies Group LLC reiterated a “hold” rating and issued a $18.00 target price on shares of NewLink Genetics Corp in a report on Friday, May 5th. Zacks Investment Research downgraded shares of NewLink Genetics Corp from a “buy” rating to a “hold” rating in a research note on Friday, March 3rd. Stifel Nicolaus reissued a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics Corp in a research note on Saturday, April 22nd. Finally, SunTrust Banks, Inc. raised shares of NewLink Genetics Corp from a “hold” rating to a “buy” rating and boosted their price target for the company from $12.00 to $30.00 in a research note on Thursday, March 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $24.00.

Receive News & Ratings for NewLink Genetics Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NewLink Genetics Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment